Skip to content
Research Article Open access CC BY 4.0

Further Review of Aspirin in the Treatment of Kawasaki Disease

Zhaoling Shi, Kai-Sheng Hsieh, Hong Wang, Xiaodong Yang, Ling Zhang, Xiangyue Kong, Jianying Feng, Juyan Wang, Fuyong Jiao

Asian Journal of Pediatric Research · pp. 13–20 · Published 5 Nov 2022

10.9734/ajpr/2022/v10i3197

Abstract

Aspirin only prevents platelets from accumulating in the dilated coronary arteries and prevents thrombosis, thus minimizing thrombosis as much as possible, and does not shrink the already dilated coronary artery tumor. Therefore, it plays an important role in the treatment of Kawasaki disease, but it is not the cause of treatment. Aspirin is common in the treatment of Kawasaki disease in children, and its effect is to reduce acute inflammatory response and alleviate platelet aggregation. Aspirin has been used to treat Kawasaki disease for more than 50 years. Since 1961, when Kawasaki discovered the first reported case of hemorrhagic shock caused by aspirin in children with Kawasaki disease, we need to re-explores the use of aspirin in the treatment of Kawasaki disease.

Aspirin Kawasaki disease coronary artery damage

Cited by 1

First principles study of 2-(acetoxy group)benzoic acid under different extremely high-pressure environments

Chao Wei, Limin Chen, Cheng Yang · Journal of Molecular Structure · 2024

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

1

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.